Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q00526
UPID:
CDK3_HUMAN
Alternative names:
Cell division protein kinase 3
Alternative UPACC:
Q00526
Background:
Cyclin-dependent kinase 3 (CDK3), also known as Cell division protein kinase 3, is a serine/threonine-protein kinase pivotal in cell cycle control, particularly during the G0-G1 and G1-S transitions. It interacts with CCNC/cyclin-C in interphase, phosphorylating key substrates such as histone H1, ATF1, RB1, and CABLES1. Phosphorylation of ATF1 by CDK3 promotes cell proliferation and transformation, while its action on RB1 is essential for the G0-G1 transition. Additionally, CDK3 is believed to facilitate G1-S transition by activating E2F1, E2F2, and E2F3 in a RB1-independent manner.
Therapeutic significance:
Understanding the role of Cyclin-dependent kinase 3 could open doors to potential therapeutic strategies.